Entry Detail
| General information | |
| Database: | DB00497 |
| Objective: | Treatment of everolimusresistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC).They report on 40 patients (pts) who receive systemic treatment after failure of everolimus. |
| Authors: | Gr¨¹nwald V, et al |
| Title: | Treatment of everolimusresistant metastatic renal cell carcinoma with VEGFtargeted therapies. |
| Journal: | Br J Cancer. |
| Year: | 2011 |
| PMID: | 22033275 |
| Trial Design | |
| Clinical Trial Id: | NA |
| Agent: | sunitinib |
| Target: | FL cytokine receptor Mast/stem cell growth factor receptor Vascular endothelial growth factor receptor 2 Plateletderived growth factor receptor |
| Cancer Type: | renal cell carcinoma |
| Cancer Subtype: | advanced renal cell carcinoma |
| Therapy Type: | com |
| Therapeutic Combination Type: | 7 |
| Therapeutic Combination Content: | sunitinib, sorafenib, dovitinib or bevacizumab/interferon |
| Study Type: | phaseIII trial |
| Key Patients Feature: | pts with everolimusresistant metastatic renal cell carcinoma |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | Forty pts received sunitinib (n=19), sorafenib (n=8), dovitinib (n=10) or bevacizumab/interferon (n=3) |
| Treatment Info: | Forty pts received sunitinib (n=19), sorafenib (n=8), dovitinib (n=10) or bevacizumab/interferon (n=3) after failure of everolimus. |
| Primary End Point: | PFS, OS and best tumour response were analysed retrospectively |
| Secondary End Point: | NA |
| Patients Number: | 40 |
| Trial Results | |
| DLT_MTD: | NA |
| Objective Response Rate: | objective partialremission (PR) in 4 pts (10%) and stable disease (SD) in 22 pts (55%) |
| Disease Control Rate: | NA |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | Treatment of everolimusresistant disease was associated with a PFS of 5.5 months. (range 0.4-22.3). Firstline VEGFtargeted therapy was associated with a median PFS of 11.3 months (range 2.2-37.6). |
| Median OS A vs. C: | The median OS from firstline VEGFtargeted therapy is 37.3 months (range 9.6-64.7). |
| Adverse Event(agent arm): | NA |
| Conclusions: | Vascular endothelial growth factor targeted therapy shows promising activity in everolimusresistant metastatic renal cancer and warrants further studies. |